Prosperity Wealth Management Inc. Has $608,000 Holdings in Mesoblast Limited (NASDAQ:MESO)

Prosperity Wealth Management Inc. trimmed its holdings in shares of Mesoblast Limited (NASDAQ:MESO - Free Report) by 47.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,700 shares of the company's stock after selling 44,545 shares during the period. Prosperity Wealth Management Inc.'s holdings in Mesoblast were worth $608,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of MESO. Barclays PLC acquired a new position in Mesoblast during the fourth quarter valued at $38,000. Lindbrook Capital LLC increased its position in Mesoblast by 70.9% in the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock worth $43,000 after purchasing an additional 901 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in Mesoblast in the 4th quarter worth about $50,000. BNP Paribas Financial Markets boosted its stake in shares of Mesoblast by 86,566.7% during the 4th quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock worth $51,000 after acquiring an additional 2,597 shares in the last quarter. Finally, Tower Research Capital LLC TRC acquired a new position in shares of Mesoblast during the 4th quarter valued at about $88,000. 1.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald raised Mesoblast to a "strong-buy" rating in a report on Monday, March 31st. One research analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Mesoblast has an average rating of "Moderate Buy" and an average target price of $18.00.

Mesoblast Trading Down 10.7%

Shares of MESO stock traded down $1.25 during trading hours on Friday, reaching $10.44. 437,599 shares of the company's stock were exchanged, compared to its average volume of 274,599. The business has a fifty day moving average price of $11.32 and a 200-day moving average price of $14.03. The company has a quick ratio of 0.63, a current ratio of 0.96 and a debt-to-equity ratio of 0.22. Mesoblast Limited has a fifty-two week low of $5.78 and a fifty-two week high of $22.00.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.